Targets › GRIN2C
2 programs from 2 companies in 4 trials: 3 Phase 2, 1 Phase 1; Psychiatry, Other; next expected readout Sep 2027.
Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+). Participates in synaptic plasticity for learning and memory formation by contributing to the slow phase of excitatory postsynaptic current and long-term synaptic potentiation (By similarity). (UniProt, Q14957)
Open in Phaseline: the race on GRIN2C, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Syndeio Biosciences | Zelquistinel Positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor | GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D | Phase 2 | Major Depressive Disorder; Healthy Volunteers in Fed and Fasted State | Sep 2027 |
| The Alfred | NMDA receptor antagonist NMDA receptor antagonist | GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D | Phase 2 | Borderline Personality Disorder | – |
Major Depressive Disorder (2) Borderline Personality Disorder (1) Healthy Volunteers in Fed and Fasted State (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.